Targeting the Carbonic Anhydrase Enzyme with Synthesized Benzenesulfonamide Derivatives: Inhibiting Tumor Growth

IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL
Zainab Kifah Abbas, Noor H. Naser, Rana Neama Atiya
{"title":"Targeting the Carbonic Anhydrase Enzyme with Synthesized Benzenesulfonamide Derivatives: Inhibiting Tumor Growth","authors":"Zainab Kifah Abbas, Noor H. Naser, Rana Neama Atiya","doi":"10.22317/jcms.v9i4.1404","DOIUrl":null,"url":null,"abstract":"Objectives: To assess the anticancer effects of recently developed compounds, Sa, Sb, Sc, and Sd. These compounds were designed to specifically target the carbonic anhydrase enzyme in solid tumors.  Methods: The chemical synthesis involved the use of sulfanilamide, chloroacetyl chloride, GABA, thionyl chloride, methanol, hydrazine hydrate, potassium hydroxide, carbon disulfide, and benzyl chloride derivatives. Docking studies were conducted using the MOE software program version 2015.10, and cytotoxic activity was predicted using the MTT assay. Results: The newly synthesized compounds exhibited notable antineoplastic activity in both in silico and cell line investigations. Although they showed a significant difference in potency compared to cisplatin against cancer cells, they also demonstrated significant differences in toxicity towards normal cells. When compared to acetazolamide, compounds Sb displayed an IC50 = 28.41 μM, which was significantly different, and compound Sd showed a non-significant difference with an IC50 = 61.20 μM against MCF7 cells. Additionally, Sb and Sd demonstrated significant difference in toxicity, with IC50 = 279.02 μM and 194.00 μM, respectively, against MCF10a cells. These findings indicate a significant difference compared to acetazolamide for the Sb compound and suggest that the synthesized compounds hold potential for further development as antineoplastic agents. Furthermore, the results from the cell line study align with the in silico study, where both compounds Sb and Sd exhibited higher S scores compared to acetazolamide, implying a stronger binding affinity with the receptor's catalytic site. The presence of a substituted 1,2,4-triazole ring in these compounds contributed to enhanced flexibility and improved interaction with the receptor. Conclusion: A new synthesized compounds exhibited cytotoxicity and demonstrated inhibitory potencies against carbonic anhydrase.","PeriodicalId":42860,"journal":{"name":"Journal of Contemporary Medical Sciences","volume":"41 1","pages":"0"},"PeriodicalIF":0.2000,"publicationDate":"2023-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Contemporary Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22317/jcms.v9i4.1404","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To assess the anticancer effects of recently developed compounds, Sa, Sb, Sc, and Sd. These compounds were designed to specifically target the carbonic anhydrase enzyme in solid tumors.  Methods: The chemical synthesis involved the use of sulfanilamide, chloroacetyl chloride, GABA, thionyl chloride, methanol, hydrazine hydrate, potassium hydroxide, carbon disulfide, and benzyl chloride derivatives. Docking studies were conducted using the MOE software program version 2015.10, and cytotoxic activity was predicted using the MTT assay. Results: The newly synthesized compounds exhibited notable antineoplastic activity in both in silico and cell line investigations. Although they showed a significant difference in potency compared to cisplatin against cancer cells, they also demonstrated significant differences in toxicity towards normal cells. When compared to acetazolamide, compounds Sb displayed an IC50 = 28.41 μM, which was significantly different, and compound Sd showed a non-significant difference with an IC50 = 61.20 μM against MCF7 cells. Additionally, Sb and Sd demonstrated significant difference in toxicity, with IC50 = 279.02 μM and 194.00 μM, respectively, against MCF10a cells. These findings indicate a significant difference compared to acetazolamide for the Sb compound and suggest that the synthesized compounds hold potential for further development as antineoplastic agents. Furthermore, the results from the cell line study align with the in silico study, where both compounds Sb and Sd exhibited higher S scores compared to acetazolamide, implying a stronger binding affinity with the receptor's catalytic site. The presence of a substituted 1,2,4-triazole ring in these compounds contributed to enhanced flexibility and improved interaction with the receptor. Conclusion: A new synthesized compounds exhibited cytotoxicity and demonstrated inhibitory potencies against carbonic anhydrase.
合成苯磺酰胺衍生物靶向碳酸酐酶:抑制肿瘤生长
目的:评价新近开发的化合物Sa、Sb、Sc和Sd的抗癌作用。这些化合物是专门针对实体肿瘤中的碳酸酐酶设计的。 方法:采用磺胺、氯乙酰氯、GABA、亚硫酰氯、甲醇、水合肼、氢氧化钾、二硫化碳和氯化苄衍生物进行化学合成。对接研究使用MOE软件程序版本2015.10进行,并使用MTT法预测细胞毒活性。 结果:新合成的化合物在硅细胞和细胞系研究中均表现出明显的抗肿瘤活性。虽然与顺铂相比,它们对癌细胞的效力有显著差异,但对正常细胞的毒性也有显著差异。与乙酰唑胺相比,化合物Sb对MCF7细胞的IC50值为28.41 μM,差异显著;化合物Sd对MCF7细胞的IC50值为61.20 μM,差异不显著。此外,Sb和Sd对MCF10a细胞的毒性差异显著,IC50分别为279.02 μM和194.00 μM。这些发现表明Sb化合物与乙酰唑胺相比具有显著差异,并表明合成的化合物具有进一步开发抗肿瘤药物的潜力。此外,细胞系研究的结果与计算机研究的结果一致,与乙酰唑胺相比,化合物Sb和Sd都表现出更高的S评分,这意味着与受体催化位点的结合亲和力更强。这些化合物中取代的1,2,4-三唑环的存在有助于增强灵活性并改善与受体的相互作用。 结论:新合成的化合物具有细胞毒性,对碳酸酐酶具有抑制作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Contemporary Medical Sciences
Journal of Contemporary Medical Sciences MEDICINE, GENERAL & INTERNAL-
自引率
0.00%
发文量
65
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信